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Treatment of squamous cell carcinoma of
the anal canal (SCCA): a new era?
There are no therapies available after progression on cisplatin
and 5-FU that can improve survival for patients with squamous
cell carcinoma of the anal canal (SCCA). Recently, two studies
have been published [1, 2] that open the era of checkpoint inhibi-
tors in SCCA.
The use of anti-PD-1 therapy in SCCA is possible because the
human papillomavirus (HPV) plays a primary role in SCCA
tumorigenesis. The risk of this malignancy is increased in patients
suffering from disorders associated with immunosuppression [3],
because this predisposes the anal epithelium to HPV infection.
In patients with SCCA, HPV is present in 90% of patients
with metastatic anal cancer. Furthermore, HPV is associated with
an increased risk of cancer of the head and neck, cervix and penis.
Cancerogenesis mediated by HPV infection is related to the viral
oncoproteins and these oncoproteins may have implications for
the rational design of immunotherapy trials in SCCA [4].
Ott et al. [1] have recently published data concerning pembro-
lizumab in patients with SCCA. In this group of patients, pem-
brolizumab showed an overall response rate of 17% with 42% of
stable disease and a disease control rate of 58% with a median
duration of 3.6 months. Median progression free survival was
3.0 months and median OS was 9.3.
Data have also been reported on nivolumab in SCCA: Morris
et al. [2] reported a median progression-free survival of
4.1 months and median overall survival of 11.5 months with a
durable response of 78% in SCCA patients treated with nivolu-
mab, with few side-effects reported. Interestingly, pre-treatment
expression of PD-1, CD-8, LAG-3 and TIM-3 showed a correla-
tion with response to nivolumab [2].
These trials open the era of checkpoint inhibitors in SCAA.
Furthermore, several studies have demonstrated that NRAS and
KRAS genes are wild-type in patients with squamous cell anal car-
cinoma [5, 6]. This suggests that cetuximab or panitumumab
could be a valid treatment strategy for these patients. Cetuximab
or panitumumab may have an effect on the immune response by
two mechanisms: complement-dependent cytotoxicity and com-
plement-dependent cell-mediated cytotoxicity.
It will be very interesting to demonstrate in future studies
whether there is an association between immunotherapy and
anti-EGFR therapy in SCCA.
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Including Lynch syndrome in personalized
prognostication and follow-up of stage II
and III colon cancer
We read with interest the paper by Dienstmann et al. [1], in
which the authors found that incorporating microsatellite in-
stability (MSI), BRAF and KRAS mutational status to overall
survival models with TNM staging increases prognostic accuracy
in stage II and III colorectal cancer (CRC) patients.
The data presented prompts some considerations on the iden-
tification of Lynch syndrome (LS) in CRC patients. As LS is
known to account for 3.3% of all CRCs [2] and approximately
1 in 5 CRC patients with high MSI, a conservative estimate of the
number of LS CRC patients in this study is 220 (3% of 7326 CRC
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